MEDICINA
Departamento
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (1)
2022
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 33, Núm. 6, pp. 616-627